β¨ Medicine Distribution Consents
16 MAY NEW ZEALAND GAZETTE 1357
Consent to the Distribution of Changed Medicines
Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the changed medicines which were referred to the Minister of Health under the provisions of section 24 (5) of the Act and are set out in the Schedule hereto:
Schedule
Product: Aerius
Active Ingredient: Desloratadine 5mg
Dosage Form: Film coated tablet
New Zealand Sponsor: Schering-Plough Pty Limited
Manufacturer: Schering-Plough SpA, Comazzo, Italy
Product: Claramax
Active Ingredient: Desloratadine 5mg
Dosage Form: Film coated tablet
New Zealand Sponsor: Schering-Plough Pty Limited
Manufacturer: Schering-Plough SpA, Comazzo, Italy
Product: Oxis Turbuhaler
Active Ingredient: Eformoterol fumarate 12Β΅g/dose
Dosage Form: Powder for inhalation
New Zealand Sponsor: AstraZeneca Limited
Manufacturer: AstraZeneca AB, Sodertalje, Sweden
Product: Oxis Turbuhaler
Active Ingredient: Eformoterol fumarate 6Β΅g/dose
Dosage Form: Powder for inhalation
New Zealand Sponsor: AstraZeneca Limited
Manufacturer: AstraZeneca AB, Sodertalje, Sweden
Dated this 10th day of May 2002.
G. R. BOYD, Chief Advisor, Safety and Regulation (pursuant to delegation given by the Minister of Health on the 20th day of February 1997).
go3284
Provisional Consent to the Distribution of a New Medicine
Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicine set out in the Schedule hereto:
Schedule
Product: Agenerase
Active Ingredient: Amprenavir 150mg
Dosage Form: Capsule
New Zealand Sponsor: Glaxo Wellcome New Zealand Limited
Manufacturer: R P Scherer SA, Beinheim, France
Note: This consent is valid for 2 years from the date of publication of this notice.
Product: Agenerase
Active Ingredient: Amprenavir 50mg
Dosage Form: Soft gelatin capsule
New Zealand Sponsor: Glaxo Wellcome New Zealand Limited
Manufacturer: R P Scherer SA, Beinheim, France
Note: This consent is valid for 2 years from the date of publication of this notice.
Product: Agenerase
Active Ingredient: Amprenavir 15mg/mL
Dosage Form: Oral solution
New Zealand Sponsor: Glaxo Wellcome New Zealand Limited
Manufacturer: Glaxo Wellcome Operations, Speke, Liverpool, United Kingdom
Note: This consent is valid for 2 years from the date of publication of this notice.
Dated this 10th day of May 2002.
G. R. BOYD, Chief Advisor, Safety and Regulation (pursuant to delegation given by the Minister of Health on the 20th day of February 1997).
go3285
Next Page →
Online Sources for this page:
VUW Te Waharoa —
NZ Gazette 2002, No 48
Gazette.govt.nz —
NZ Gazette 2002, No 48
β¨ LLM interpretation of page content
π₯
Consent to Distribution of Changed Medicines
(continued from previous page)
π₯ Health & Social Welfare10 May 2002
Medicines, Distribution, Consent, Medicines Act 1981, Changed Medicines
- G. R. Boyd, Chief Advisor, Safety and Regulation
π₯ Provisional Consent to Distribution of New Medicine
π₯ Health & Social Welfare10 May 2002
Medicines, Provisional Consent, Distribution, Medicines Act 1981, New Medicine
- G. R. Boyd, Chief Advisor, Safety and Regulation